BRIP1抗体;BRIP1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using BRIP1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using BRIP1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using BRIP1 mouse mAb with DAB staining.    

  
  

BRIP1 (BRCA1-interacting protein 1), also known as FANCJ, is a DNA helicase critical for DNA repair and genomic stability. It interacts directly with BRCA1. a key tumor suppressor, facilitating homologous recombination repair (HRR) of double-strand DNA breaks. BRIP1 mutations are linked to Fanconi anemia (complementation group J) and increased susceptibility to breast, ovarian, and other cancers. Dysfunctional BRIP1 impairs DNA damage response, leading to error-prone repair and chromosomal instability.

BRIP1 antibodies are essential tools for studying its expression, localization, and functional roles in cancer biology and DNA repair mechanisms. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to quantify BRIP1 protein levels in tissues or cell lines. Reduced BRIP1 expression, detected via these antibodies, may indicate pathogenic mutations or epigenetic silencing, serving as a biomarker for cancer risk assessment or therapeutic stratification. In research, BRIP1 antibodies help elucidate interactions with BRCA1 and other repair proteins, shedding light on HRR pathway dynamics. Clinically, they aid in identifying patients with BRIP1-deficient tumors, which may exhibit sensitivity to PARP inhibitors or platinum-based therapies. However, antibody specificity and validation remain critical challenges due to BRIP1’s structural homology with other helicases.